Evaluation of the Predictive Value of 18F-fluorodeoxyglucose Positron Emission Tomography and Brain Perfusion Computed Tomography for the Efficacy of Anti-angiogenic Therapy (Bevacizumab) in Recurrent Glioblastoma

Inclusion Criteria

• •The patient must have given their free and informed consent and signed the consent form
• •The patient must be a member or beneficiary of a health insurance plan
• •The patient has an WHO score ≤ 3
• •The patient's estimated life expectancy is more than 3 months.
• •Patient with histologically proven diagnosis of glioblastoma.
• •Patient presenting with tumor progression on morphological MRI confirmed by a multidisciplinary committee.
• •Patient with a unilateral supratentorial target lesion upon inclusion to establish a tumor region of interest (ROI) zone and an equivalent ROI zone in contralateral healthy tissue.
• •Patient progressing after radiotherapy and at least one line of chemotherapy with TEMODAL
• •Patient in whom treatment with Bevacizumab monotherapy has been validated by a multidisciplinary committee.